CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. MARKET ACCESS SERVICES AGREEMENTMarket Access Services Agreement • November 12th, 2020 • Myovant Sciences Ltd. • Pharmaceutical preparations • Delaware
This Market Access Services Agreement (this “Agreement”) is entered into as of August 1, 2020 (the “Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Myovant Sciences GmbH, a Swiss company, having a principle place of business at Viadukstrasse 8, 4051 Basel, Switzerland (“Myovant”). Sunovion and Myovant may individually be referred to as a “Party” and collectively as the “Parties”.
MARKET ACCESS SERVICES AGREEMENTMarket Access Services Agreement • August 13th, 2020 • Urovant Sciences Ltd. • Pharmaceutical preparations • Delaware
This Market Access Services Agreement (this “Agreement”) is entered into as of June 17, 2020 (the “Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Urovant Sciences GmbH, a Swiss corporation, having a principle place of business at Aeschenvorstadt 4, CH-4010, Viaduktstrasse 8, 4051 Basel, Switzerland (“Urovant”). Sunovion and Urovant may individually be referred to as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO MARKET ACCESS SERVICES AGREEMENTMarket Access Services Agreement • February 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) is entered into as of December 14, 2020 (the “Amendment Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Myovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).
MARKET ACCESS SERVICES AGREEMENTMarket Access Services Agreement • November 21st, 2012 • Ardent Mines LTD • Gold and silver ores • New York
This Market Access Services Agreement (this “Agreement”) is made and entered into this 11th day of September, 2012, by Ardent Mines (the “Company”), a Nevada corporation having offices at 100 Wall Street NewYork, NY United States, 10005 and Monarch Media LLC, a Nevada limited liability corporation having an office at Suite 18, 3136 South Eastern Avenue, Las Vegas NV 89169 (the “Consultant”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Amendment No. 1 to Market Access Services AgreementMarket Access Services Agreement • February 12th, 2021 • Urovant Sciences Ltd. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) to the Agreement (defined below) is entered into by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Urovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Urovant”). Sunovion and Urovant may individually be referred to as a “Party” and collectively as the “Parties”. This Amendment is effective as of December 21, 2020 (the “Amendment Effective Date”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 2 TO MARKET ACCESS SERVICES AGREEMENTMarket Access Services Agreement • February 12th, 2021 • Urovant Sciences Ltd. • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”) is entered into as of January 8, 2021 (the “Amendment Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Urovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Urovant”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).
AMENDMENT NO. 2 TO MARKET ACCESS SERVICES AGREEMENTMarket Access Services Agreement • May 11th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”) is entered into as of January 25, 2021 (the “Amendment Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Myovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).
